Written by Amal Allam
Thursday, May 18, 2023 05:25 PM
The World Health Organization said in a new statement, that the WHO technical advisory group on the formation of the Corona vaccine continues to meet regularly to assess the implications of the development of Corona to form a vaccine antigen, and to advise the World Health Organization on whether changes in the composition of the antigen are needed. Future Corona Vaccines.
In April 2023, the WHO technical advisory group on the composition of the Corona vaccine indicated TAG-CO-VAC The advisory group will meet at least twice in 2023, once in May 2023, and again about 6 months later. At each meeting, recommendations will be issued to maintain the current vaccine formulation or to consider updates.
The frequency of the evidence review is approved by the WHO Technical Advisory Group on Vaccine Formulation TAG-CO-VAC on the kinetics of vaccine-derived immunity and the need for continuous monitoring of the development of the MERS-CoV vaccine, and it will be modified if necessary.
The WHO Technical Advisory Group on Corona Vaccine Formulation met on May 11-12, 2023 to review the genetic and antigenic evolution of the Coronavirus, and the performance of currently approved vaccines against circulating Corona variants.
The organization said, as previously stated by the advisory group, the goal of updating the antigen composition of the Corona vaccine is to enhance vaccine-induced immune responses to circulate vaccine variants. This statement and recommendation for change are directed to all vaccine manufacturers and aim to inform future formulations of Corona vaccines.
The organization explained: you realize TAG-CO-VACThe Advisory Group reiterates that currently approved Corona vaccines, including those based on the virus, continue to provide significant protection against severe illness and death, which is the primary goal of vaccination against Corona, the use of currently approved Corona vaccines must continue according to the SAG Vaccine Roadmap of the World Health Organization WHO SAGE published April 2023 Although protection against severe disease, protection against symptomatic disease is limited, new formulations of coronavirus vaccines are needed to improve protection against symptomatic disease.